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Purpose: Prostate-speciﬁc antigen (PSA) is a surrogate marker of disease progression; however, its
predictive ability in the extreme ranges is unknown. We determined the predictors of survival in patients
with bone metastatic prostate cancer (BMPCa) and with extremely high PSA levels.
Methods: Treatment-naïve patients (n ¼ 248) diagnosed with BMPCa between December 2002 and June
2012 were retrospectively analyzed. Clinicopathological features at diagnosis, namely age, body mass
index, serum alkaline phosphatase (ALP) and PSA levels, PSA nadir, time to PSA nadir and its maintenance
period, PSA declining velocity, Gleason grade, clinical T stage, pain score, Eastern Cooperative Oncology
Group performance score (ECOG PS), and the number of bone metastases were assessed. The patients
were stratiﬁed according to PSA ranges of <20 ng/mL, 20e100 ng/mL, 100e1000 ng/mL, and 1000
e10,000 ng/mL. Study endpoints were castration-resistant PCa (CRPC)-free survival and cancer-speciﬁc
survival (CSS).
Results: Patients with higher PSA and ALP levels showed more bone lesions (P < 0.001). During the
follow-up period (median, 39.9 months; interquartile range, 21.5e65.9 months), there were no differ-
ences between the groups in terms of the survival endpoints. High ALP levels, shorter time to PSA nadir,
and painwere associated with an increased risk of progression to CRPC, and high ALP levels, ECOG PS  1,
and higher PSA nadir independently predicted CSS.
Conclusions: PSA response to androgen deprivation therapy and serum ALP are reliable predictors of
survival in patients with BMPCa presenting with extremely high PSA levels. These patients should not be
deterred from active treatment based on baseline PSA values.
© 2015 Published by Elsevier B.V. on behalf of Prostate International. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Over the course of the prostate-speciﬁc antigen (PSA) era, pa-
tients have presented with prostate cancer (PCa) at a younger age
and with lower grade disease, and are now more likely to present
with organ-conﬁned cancers.1 However, bone metastasis still oc-
curs in approximately 3% of all newly diagnosed patients. In a
previous study, 12% of patients without initial evidence were found
to develop bone metastases during a median follow-up of 2.2
years.2,3 In advanced stage PCa, bone is the most common site of
metastasis, representing >80% of all cases, and this is associated
with a high risk of morbidity.4 Given the heterogeneous naturalYonsei University College of
South Korea.
ier B.V. on behalf of Prostate Intecourse of bonemetastatic PCa (BMPCa), determining the prognostic
clinicopathological features for survival is critical for patient
counseling and to ensure judicious application of multimodal
treatments.
PSA is a surrogate marker of systemic progression and cancer-
speciﬁc survival (CSS).1 Most prediction models deﬁne high risk
PCa as a presenting PSA level of >20 ng/mL.5 However, the ability of
an extremely high PSA level to reﬂect disease burden and its
prognostic impact on survival has not been well described. Given
the relationship between elevated PSA levels and inferior survival
outcome, the concern about poorer outcome further intensiﬁes
when the PSA values are extremely elevated. Indeed, it is of sub-
stantial importance to identify patients at the highest risk of sys-
temic dissemination, as aggressive deﬁnitive therapy targeting PCa
may detrimentally impact the quality of life and performance status
of these patients, without having any survival beneﬁts.rnational. This is an open access article under the CC BY-NC-ND license (http://
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ferential survival outcomes of patients with BMPCa and extremely
high PSA levels. Hence, there is uncertainty regarding the clinical
utility of PSA at this stage of the disease, and the optimal man-
agement and extent of treatment remain unclear. In this study, we
aimed to investigate the predictors of castration-resistant PCa
(CRPC)-free survival and CSS in patients initially diagnosed with
BMPCa presenting with extremely high serum PSA levels. We
believe that the relatively uncommon ﬁnding of a PSA level of such
a great magnitude and the paucity of data pertaining to survival
outcome in this population lend relevance to this study.
2. Methods
2.1. Study population
A retrospective analysis was performed using a prospectively
collected database of 248 consecutive treatment-naïve patients
diagnosed with BMPCa between December 2002 and June 2012.
PCa staging was determined according to the seventh American
Joint Committee on Cancer TNM system,with the deﬁnition of bone
metastasis based on either demonstrable metastatic deposits upon
imaging studies (bone scan, computed tomography, magnetic
resonance imaging, or positron emission tomography) or by path-
ologic conﬁrmation. Patients were excluded from the analysis if
they met the following criteria: (1) incomplete clinical data, (2)
presence of visceral metastasis, (3) presence of nonregional lymph
node enlargement, (4) lost to follow-up, or (5) unknown cause of
death. The initiation and regimen of intermittent or continuous
androgen-deprivation therapy (ADT), secondary hormonal manip-
ulations, and cytotoxic chemotherapywere decided at each treating
physician's discretion.
2.2. Prognostic factors and outcome variables
The clinical and pathological characteristics of the patients at
diagnosis were retrieved from the institutional electronic medical
record database. The data obtained consisted of age, baseline serum
PSA and alkaline phosphatase (ALP) levels, PSA nadir, time to PSA
nadir (TTN) and its maintenance period, PSA declining velocity,
body mass index, Eastern Cooperative Oncology Group perfor-
mance score (ECOG PS), Visual Analogue Scale pain score, Charlson
Comorbidity Index, biopsy Gleason score, clinical T stage, progres-
sion to CRPC, and the number of metastatic bone lesions.
CRPC was deﬁned as progression of disease or elevation of
serum PSA using the Prostate Cancer Working Group 2 criteria,6
with the CRPC-free interval deﬁned as the time from the date of
the ﬁrst radiographic bonemetastasis to the date of CRPC diagnosis.
The CSS interval was deﬁned as the interval from the ﬁrst date of
diagnosis to the date of death from PCa. Patient data were
considered missing if any of the above data were absent.
For the analyses, patients were stratiﬁed according to the
following logarithmically scaled PSA ranges: <20 ng/mL,
20e100 ng/mL, 100e1000 ng/mL, and 1000e10,000 ng/mL. Patient
survival and causes of death were investigated based on the Na-
tional Cancer Registry Database or institutional electronic medical
records. This study was approved by the institutional ethics com-
mittee after review of the protocol and procedures employed (3-
2014-0112).
2.3. Statistical analysis
The clinicodemographic characteristics of the patients and tu-
mors were compared using descriptive statistics. Appropriate
comparative tests, such as analysis of variance and Fisher's exacttest, were used to compare continuous and categorical variables.
KaplaneMeier curves were used to estimate the CRPC-free survival
and CSS according to PSA, ALP, PSA nadir, and TTN, stratiﬁed by
given cutoff values. Multivariate analysis was performed using Cox-
proportional hazards regression models in order to adjust for po-
tential confounders in predicting survival. Variables considered as
potential predictors for multivariate modeling were selected by
univariate analyses and subsequently tested in a stepwise forward
conditional manner, with entry and retention in the model set at a
signiﬁcance level of 0.05. All statistical analyses were performed
using SPSS version 18 (SPSS Inc., Chicago, IL, USA). All tests were
two-sided, with statistical signiﬁcance set at P < 0.05.
3. Results
3.1. Patient characteristics
The clinicopathologic features of each group are presented in
Table 1. Patients with higher PSA levels weremore likely to progress
to CRPC, to harbor a greater number of metastatic bone lesions, and
to have higher ALP levels than were patients with lower PSA levels.
Of note, there were no differences in the distributions of biopsy
Gleason grade, clinical T stage, and CSS rates between the PSA
groups. Patients with ALP levels 200 IU/L harbored a greater
number of metastatic bone lesions than those with ALP levels <200
IU/L (P < 0.001; data not shown).
3.2. Predictors of survival
The adjusted proportional hazard regression analyses for the
potential prognostic factors of CRPC-free survival and CSS are
summarized in Tables 2 and 3, respectively. High ALP level, shorter
TTN, and the presence of pain were found to be associated with
increased risks of progression to CRPC, whereas high ALP level, high
PSA nadir, and ECOG PS  1 independently predicted cancer-
speciﬁc mortality.
3.3. Survival outcome
Survival data as of March 2014were used in this analysis. During
the median follow-up period of 39.9 months (interquartile range,
21.5e65.9 months), there were no differences in the CRPC-free
survival and CSS between the different PSA groups (Figs. 1A and
2A). Comparative survival outcomes of covariates considered po-
tential predictors by the Cox-proportional hazards analysis were
analyzed according to each cutoff value. Patients with high ALP
levels (200 IU/L) were found to have signiﬁcantly worse CRPC-
free survival (P ¼ 0.001) and CSS (P ¼ 0.005) compared to pa-
tients with ALP levels < 200 IU/L (Figs. 1B and 2B). Moreover, pa-
tients who achieved a PSA nadir value of0.2 ng/mL following ADT,
revealed worse CSS compared to those with PSA nadir <0.2 ng/mL
(P ¼ 0.001; Fig. 2C). However, PSA nadir was not associated with an
increased risk of CRPC progression (P¼ 0.614; Fig.1C). Patients with
a TTN of <9 months showed signiﬁcantly worse CRPC-free survival
(P ¼ 0.024) and CSS (P ¼ 0.022) compared to those with TTN of 9
months (Figs. 1D and 2D).
4. Discussion
Most risk stratiﬁcation schemes deﬁne high risk disease as a
presenting PSA level of >20 ng/mL.1,5 In localized PCa, serum PSA
has been demonstrated to correlate with the pathological stage,
Gleason score, and the probability of organ-conﬁned disease 7,8;
whereas, in metastatic PCa, PSA has been shown to reﬂect the
disease burden, and its post-hormone therapy response serves as a
Table 1
Clinical and pathological features of 248 patients initially diagnosed with bone-metastatic prostate cancer.
PSA group (ng/mL) <20 20e100 100e1000 1000e10,000 P
N (%) 39 (15.7) 89 (35.9) 90 (36.3) 30 (12.1) NS
Age (y) 73 (67e79) 65 (58e72) 71.5 (66.5e76.5) 71 (65.5e76.5) 0.803
BMI (kg/m2) 25.5 (23e28.1) 22.9 (20.3e25.5) 22.7 (20.3e25.1) 23.7 (20.6e26.9) 0.813
ECOG PS (1) 7 (17.9) 24 (26.9) 20 (22.2) 11 (36.7) 0.728
CCI (4) 32 (82.1) 67 (75.3) 68 (75.6) 24 (80.0) 0.744
VAS pain score (1) 9 (23.1) 26 (29.2) 42 (46.7) 14 (46.7) 0.086
T stage 0.409
T2 10 (25.6) 7 (7.9) 8 (8.9) 2 (6.7)
T3 23 (59.1) 49 (55.1) 40 (44.5) 18 (60.0)
T4 6 (15.3) 33 (37.0) 42 (46.6) 10 (33.3)
Gleason grade 0.114
7 11 (28.2) 23 (25.8) 15 (16.8) 1 (3.3)
8 13 (33.3) 29 (32.6) 35 (38.9) 13 (43.3)
9 15 (38.5) 37 (41.6) 40 (44.3) 16 (53.4)
ALP (IU/L) 117 (71.0e196.3) 82.0 (71.0e107) 98.0 (72.5e191) 157 (93.0e389) 0.002
Time to PSA nadir (mo) 5.0 (3.0e6.0) 7.0 (5.0e12.0) 5.5 (4.0e10.3) 6.0 (5.0e10.0) 0.763
PSA nadir (ng/mL) 1.83 (0.01e5.5) 0.36 (0.02e1.6) 0.93 (0.09e5.98) 11.6 (0.27e25.4) 0.343
PSA nadir maintenance period (mo) 10.0 (6.5e23.5) 13.0 (8.0e18.0) 9.0 (6.0e19.0) 12.0 (8.0e18.0) 0.411
PSA velocity (ng/mL/mo) 10.0 (2.7e39.2) 11.3 (3.9e18.1) 45.3 (26.2e101.1) 472 (176e817) 0.051
Progression to CRPC 9 (23.1) 41 (46.1) 60 (66.7) 20 (66.7) 0.001
No. of bone lesions <0.001
5 17 (43.6) 41 (46.1) 27 (30.0) 2 (6.7)
6e20 11 (28.2) 41 (46.1) 30 (33.3) 6 (20.0)
>21 11 (28.2) 7 (7.8) 33 (36.7) 22 (73.3)
Follow-up period (mo) 39.9 (21.5e49.8) 39.1 (24.8e58.2) 41.2 (20.6e60.3) 26.9 (18.4e56.8) 0.607
Data arepresented as n (%) and median (interquartile range).
ALP, alkaline phosphatase; BMI, body mass index; CCI, Charlson Comorbidity Index; CRPC, Castrate-resistance prostate cancer; ECOG PS, Eastern Cooperative Oncology Group
performance score; LN, lymph node; PSA, prostate-speciﬁc antigen; VAS, Visual Analogue Scale.
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population-based observational studies, a PSA level >50 ng/mL was
observed to correlate with extreme-risk patients, who showed a
worse response to treatment and survival outcome than other high
risk patients.7,9,10 Therefore, it is conceivable that the high risk
population includes a subset of patients who are at an extreme risk
for disease progression and mortality.
The natural history of metastatic PCa is heterogeneous, and the
diagnostic and treatment dilemmas intensify when a patient pre-
sents with extremely high PSA levels. Although an extremely high
PSA level is commonly acknowledged to indicate extreme riskTable 2
Predictors of progression to castration-resistant disease in patients with bone
metastatic prostate cancer.
Univariate Multivariatea
HR (95% CI) P HR (95% CI) P
Age (y) 0.991 (0.967e1.016) 0.471
BMI 1.027 (0.963e1.095) 0.422
Gleason score (8) 1.759 (1.068e2.898) 0.027
T stage (T3) 1.195 (0.484e2.947) 0.701
Baseline PSA 1.000 (0.998e1.001) 0.593
Time to PSA nadir 0.916 (0.859e0.977) 0.008 0.877 (0.812e0.947) 0.001
PSA nadir 1.000 (0.993e1.006) 0.931
PSA nadir
maintenance
period
0.968 (0.939e0.998) 0.041
PSA velocity 1.000 (1.000e1.000) 0.603
Baseline ALP 1.001 (1.001e1.002) <0.001 1.001 (1.000e1.002) 0.007
VAS pain score (1) 1.519 (1.022e2.258) 0.039 3.061 (1.434e6.531) 0.004
ECOG PS (1) 1.141 (0.741e1.760) 0.552
Number of bone
lesions
1.016 (0.997e1.036) 0.095
ALP, alkaline phosphatase; BMI, body mass index; CCI, Charlson Comorbidity Index;
CI, conﬁdence interval; CRPC, Castrate-resistance prostate cancer; ECOG PS, Eastern
Cooperative Oncology Group performance score; HR, hazards ratio; LN, lymph node;
PSA, prostate-speciﬁc antigen; VAS, Visual Analogue Scale.
a Forward step-wise conditional method.disease, no stratiﬁcationmodel has yet demonstrated its prognostic
value in this setting.11 If a patient diagnosed with BMPCa would be
expected to have an unfavorable survival outcome based on an
extremely high PSA level, this patient may not be regarded as a
candidate for aggressive treatment, as this may have detrimental
impacts on the quality of life and performance status of the patient
without any survival beneﬁts. For these reasons, in an initial
attempt to investigate this issue, we limited the patient population
in this study to menwith BMPCa, which may limit the confounding
variables and potentially provide a more accurate assessment of aTable 3
Predictors of cancer-speciﬁc mortality in patients with bone metastatic prostate
cancer.
Univariate Multivariatea
HR (95% CI) P HR (95% CI) P
Age (y) 1.009 (0.985e1.034) 0.447
BMI 1.044 (0.961e1.135) 0.315
Gleason score (8) 2.663 (1.421e4.994) 0.002
T stage (T3) 1.529 (0.705e3.318) 0.282
PSA 1.001 (0.999e1.002) 0.295
Time to PSA nadir 0.879 (0.808e0.956) 0.003
PSA nadir 1.001 (1.001e1.002) 0.002 1.006 (0.001e1.011) 0.012
PSA nadir
maintenance
period
0.924 (0.868e0.962) 0.003
PSA velocity 1.000 (1.000e1.000) 0.149
ALP 2.121 (1.353e3.324) 0.001 1.002 (1.001e1.003) 0.016
VAS pain score (1) 2.079 (1.309e3.301) 0.002
ECOG PS (1) 2.238 (1.385e3.616) 0.001 2.685 (1.287e5.605) 0.009
Progression to CRPC 2.255 (1.442e3.526) <0.001
Number of bone
lesions
1.017 (0.997e1.037) 0.102
ALP, alkaline phosphatase; BMI, body mass index; CCI, Charlson Comorbidity Index;
CI, conﬁdence interval; CRPC, Castrate-resistance prostate cancer; ECOG PS, Eastern
Cooperative Oncology Group performance score; HR, hazards ratio; LN, lymph node;
PSA, prostate-speciﬁc antigen; VAS, Visual Analogue Scale.
a Forward step-wise conditional method.
Fig. 1. Comparative survival curves of patients with bone metastatic prostate cancer for progression to castration-resistant prostate cancer (CRPC)-free survival. (A) Survival curve
stratiﬁed according to serum prostate-speciﬁc antigen (PSA) levels. (B) Survival curve stratiﬁed according to serum alkaline phosphatase (ALP) levels dichotomized at 200 IU/L. (C)
Survival curve stratiﬁed according to PSA nadir levels dichotomized at 0.2 ng/mL. (D) Survival curve stratiﬁed according to time to PSA nadir (TTN) dichotomized at 9 months.
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useful.
Bone metastasis in PCa is characterized by a distinct clinical
pattern of bone-forming metastasis.12 Among the various bone-
related biochemical markers that are known to be elevated in pa-
tients with BMPCa,13,14 serum ALP is a representative bone forma-
tion marker that has been demonstrated to be associated with both
the extent of bone metastasis and survival.15,16 The importance of
serum ALP as a prognostic factor for survival in metastatic PCa has
been emphasized in previously developed survival models, in
which the patient performance status as well as hemoglobin, al-
bumin, lactate dehydrogenase, and ALP levels, was demonstrated to
be signiﬁcantly associated with overall survival.17e19 Our study
conﬁrmed patient performance status and serum ALP levels as in-
dependent predictors, even in patients with BMPCa presenting
with extremely high PSA levels. Of note, our multivariate analysis
revealed oncological features such as clinical T stage or Gleason
grade to have only modest effects on survival outcome, which was
also consistent with the results of certain previous studies.20,21
However, the inclusion of only patients with BMPCa who tended
to have high risk disease may have limited the discriminatory value
of these variables.In clinical practice, PSA is the most widely utilized surrogate and
prognostic marker used to evaluate disease burden and to predict
survival prognosis.22 PSA has been shown to correlate with
increased risks of bone-related clinical outcomes and overall sur-
vival in patients with metastatic CRPC23; and, moreover, in men
with nonmetastatic CRPC, a higher PSA has been found to be
associated with a shorter time to bone metastasis and reduced
overall survival.14 However, it should be noted that the cohorts of
these previous studies consisted of patients with relatively low PSA
levels. Hence, our ﬁndings are of particular importance, given that
extremely high PSA levels failed to show associations with all sur-
vival endpoints. Furthermore, the results of the current study are
consistent with previous reports of patients on ADT, in which the
association between baseline PSA and time to progression was
conﬁned only to nonmetastatic patients.24
PSA kinetics following ADT, namely, PSA nadir, TTN, and PSA
velocity, have been shown to be useful predictors of disease pro-
gression and survival in various disease settings.25 Previous studies
have reported a signiﬁcant association between PSA nadir and
progression to CRPC.20,26 Although there is currently no consensus
on the optimal threshold of PSA nadir, we used the most widely
reported cutoff value of 0.2 ng/mL in this study, and found that PSA
Fig. 2. Comparative survival curves of patients with bone metastatic prostate cancer for cancer-speciﬁc survival. (A) Survival curve stratiﬁed according to serum prostate-speciﬁc
antigen (PSA) levels. (B) Survival curve stratiﬁed according to. serum alkaline phosphatase (ALP) levels dichotomized at 200 IU/L. (C) Survival curve stratiﬁed according to. PSA nadir
levels dichotomized at 0.2 ng/mL. (D) Survival curve stratiﬁed according to time to PSA nadir (TTN) dichotomized at 9 months.
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wise, there is also no consensus regarding the optimal threshold of
TTN for predicting survival outcomes, and various studies have
reported conﬂicting cutoff values, varying according to each study
setting.27,28 Herein, we showed that a cutoff period of 9monthswas
capable of distinguishing patients with favorable CRPC-free sur-
vival and CSS rates; these ﬁndings are consistent with those of
recent studies, which have reported that a longer TTN is associated
with longer remission and survival.29,30 Although the exact mech-
anism underlying the association between PSA kinetics and sur-
vival prognosis is unclear, our results highlight the fact that the
prognosis of patients diagnosed with BMPCa with extremely high
PSA levels depends on multiple patient factors. Based on our re-
sults, we support the use of PSA kinetics following ADTand baseline
serum ALP as alternative prognostic markers to PSA for risk strat-
iﬁcation at this stage of the disease.
The main strength of the current study was the incorporation of
detailed clinicopathological data, including information on treat-
ment, comorbidities other than cancer, and performance status,
available from each patient. Moreover, the use of a single institu-
tional cohort may ensure uniformity of the data. However, at the
same time, there were several potential limitations worthmentioning. The ﬁrst is the retrospective nature of the study. This
design is associated with a lack of a standard therapeutic approach,
and strong patient and physician preferences existed regarding the
implementation of speciﬁc treatments. As such, the indication to
initiate therapy, choice of treatment modality, administration in-
tervals, and type of agents lacked standardization. Nevertheless, we
believe that this effect is inherent in any retrospective study and
may reﬂect the real-world clinical practice inwhich the application
of sequential therapies for metastatic PCa is not standardized.
Secondly, our study cohort was limited to patients with BMPCa, and
the prognostic factors identiﬁed were not determined until
metastasis had developed. Thus, the results may not be generaliz-
able to evaluating the risk for patients diagnosed with other me-
tastases or after a certain treatment. However, despite these
limitations, the current study provided information regarding the
long-term survival outcomes in a unique cohort of potentially
extreme-risk patients, for whom risk stratiﬁcation is controversial.
An extreme serum PSA level reﬂects the disease burden of
BMPCa; however, it is not prognostic for CRPC-free survival or CSS.
Patients with BMPCa initially presenting with extremely high PSA
levels should not be deterred from active treatment and should be
given a deﬁnitive therapeutic goal, as these patients may show
K.C. Koo et al. / Prostate International 3 (2015) 10e15 15comparable survival outcomes to that of men with relatively low
PSA levels. Moreover, our observations support the use of the PSA
response to ADT and serum ALP levels as alternative predictors of
survival in these patients.
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